Delayed PCI 12 Hours after the Onset of Symptoms Is Associated with Improved Outcomes for Patients with ST-Segment Elevation Myocardial Infarction: A Real-World Study.

Abstract

BACKGROUND:

Primary percutaneous coronary intervention (PPCI) plays a pivotal role in the treatment of ST-segment elevation myocardial infarction (STEMI). However, it remains controversial whether PCI delayed beyond the recommended time window of 12 h after the onset of symptoms is applicable to STEMI.

OBJECTIVE:

The acute myocardial infarction (AMI) registration study in Xinjiang, China, is a real-world clinical trial (retrospective cohort study) that includes hospitalized patients. The purpose of this study was to compare delayed PCI and medication therapy beyond the recommended time window of 12 h after the onset of symptoms on the outcomes of STEMI patients.

METHODS AND RESULTS:

From May 2012 to December 2015, a total of 1072 STEMI patients received delayed PCI (n=594) or standard medication therapy (MT) (n=478) more than 12 h after the onset of symptoms. The number of all-cause deaths in the delayed PCI group and that in the MT group were 55 (9.3%) and 138 (28.9%), respectively, and a significant difference between the groups was indicated for this variable (P<0.001). The number of cardiac deaths in the delayed PCI group and that in the medication therapy group were 47 (7.9%) and 120 (25.1%), respectively, and a significant difference between the groups was indicated for this variable (P<0.001). We also found that the MACE incidence in the delayed PCI group was significantly higher than it was in the MT group (32.2% versus 43.5%, P<0.001). Propensity score matching (PSM) analyses remained significant differences between the delayed PCI group and the MT group, respectively, in all-cause deaths (9.3% versus 25.8%, P<0.001) and cardiac death (8.7% versus 21.6%, P<0.001).

CONCLUSION:

Compared to medication therapy, PCI for STEMI delayed beyond 12 h after the onset of symptoms can better reduce mortality and the incidence of MACEs.

TRIAL REGISTRATION:

This study is registered with the following: Trial Registration: clinicaltrials.gov; Identifier: NCT02737956.

• Authors: Wen-Juan Xiu, Hai-Tao Yang, Ying-Ying Zheng, Yi-Tong Ma, Xiang Xie
• Journal: Journal of interventional cardiology (J Interv Cardiol) Vol. 2019 Pg. 2387929 ( 2019) ISSN: 1540-8183 [Electronic] United States
• PMID: 31772517 (Publication Type: Journal Article, Multicenter Study, Observational Study)
• Copyright: Copyright © 2019 Wen-Juan Xiu et al.

Chemical References

• Heparin, Low-Molecular-Weight
• Platelet Aggregation Inhibitors
• Platelet Glycoprotein GPIIb-IIIa Complex
• Clopidogrel
• Aspirin

Topics

• Adult
• Aged
• Aged, 80 and over
• Aspirin (therapeutic use)
• China (epidemiology)
• Clopidogrel (therapeutic use)
• Female
• Heparin, Low-Molecular-Weight (therapeutic use)
• Humans
• Male
• Middle Aged
• Percutaneous Coronary Intervention
• Platelet Aggregation Inhibitors (therapeutic use)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• ST Elevation Myocardial Infarction (mortality, therapy)
• Time-to-Treatment
• Young Adult